FIGS. 19A and 19B show a dermal angiogenesis assay

FIGS. 19A and 19B show a dermal angiogenesis assay. In order for a tumor to grow larger than 2 mm diameter, new host blood vessels must be induced. SW480 tumor cells (2x106) were inoculated in suspension in a volume of 0.1 ml PBS into the dermis of humanized NSG mice. Mice were treated with 2 mg of either IgG or leronlimab administered intradermally 2x/wk. Ten days later, mice were euthanized and the inoculation site was photographed under 12.5x magnification. VESGEN software was used to analyze vessel number, diameter, branching, vessel generation number, and network characteristics. Assignment of vessels to branching generations G1-G9 by VESGEN. The VESGEN output image of a specimen here illustrates the classification of vessels into ten successively smaller branching generations (G1-G9) for the arterial end point region. Vessel branching generations are determined by (1) decrease in vessel diameter and (2) vessel bifurcations that are approximately symmetric (i.e. , when diameters of offspring vessels branching from a parent vessel are approximately equal).
FIG. 19A shows the photomicrographs and vessel size analysis. FIG. 19B shows quantified data for total vessel area, vessel length density, number of vessels, and tumor area. Leronlimab-treated mice had over 2-fold reduction in neo vessel formation compared to IgG treated mice, evidenced by decrease in total pixel count, vessel length density, and overall number of vessels. Most dramatic was reduction of smaller vessels (Generation 4 - 9), as compared to larger vessels (Generation 1 - 3).
DETAILED DESCRIPTION
The instant disclosure provides methods for treating or preventing a cancer comprising administering a competitive inhibitor to a CCR5 cell receptor. In some embodiments, the competitive inhibitor comprises leronlimab, or a binding fragment thereof.